Involvement of c-Src kinase in the regulation of TGF-β1-induced apoptosis

Transforming growth factor-β1 (TGF-β1) is a potent inducer of apoptosis in normal hepatocytes, and acquiring resistance to TGF-β1 may be a critical step in the development of hepatocellular carcinoma (HCC). In this study, we investigated the possible involvement of c-Src in the regulation of TGF-β1-...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 23; no. 37; pp. 6272 - 6281
Main Authors SEOK SOON PARK, EOM, Young-Woo, EUN HEE KIM, JI HYUN LEE, DO SIK MIN, KIM, Sungsub, KIM, Seong-Jin, KYEONG SOOK CHOI
Format Journal Article
LanguageEnglish
Published Basingstoke Nature Publishing 19.08.2004
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Transforming growth factor-β1 (TGF-β1) is a potent inducer of apoptosis in normal hepatocytes, and acquiring resistance to TGF-β1 may be a critical step in the development of hepatocellular carcinoma (HCC). In this study, we investigated the possible involvement of c-Src in the regulation of TGF-β1-induced apoptosis. TGF-β1 induced transient activation of c-Src and its subsequent caspase-mediated degradation concomitant with cell death in FaO hepatoma cells, which are sensitive to TGF-β1. In response to TGF-β1, activated c-Src was translocated into the cytoplasmic membrane, then relocated to the nuclei of apoptotic cells during its cleavage. In TGF-β1-induced apoptotic cells, c-Src maintained its tight association with p85 FAK fragment cleaved by caspases, possibly contributing to focal adhesion disassembly. TGF-β1-induced apoptosis was enhanced by either inhibition of c-Src activity using PP1 or PP2, or by overexpression of dominant-negative c-Src. In contrast, overexpression of constitutively active c-Src inhibited apoptosis suppressing TGF-β1-induced activation of p38, JNK and caspases. In many HCC cell lines resistant to TGF-β1, enhanced c-Src activity was detected. We hypothesize that activated c-Src in HCC may contribute to resistance against the apoptotic and/ or antiproliferative properties of TGF-β1.
ISSN:0950-9232
1476-5594
DOI:10.1038/sj.onc.1207856